TELA Bio, Inc. 8-K

What Happened

• TELA Bio, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release dated May 12, 2026. The press release was furnished as Exhibit 99.1 to the company’s Form 8-K (Item 2.02).
• On the same day, the company updated its corporate slide deck for use in investor meetings and furnished that presentation as Exhibit 99.2 (Item 7.01), as part of its Regulation FD disclosure.

Key Details

• Press release announcing quarterly results: dated May 12, 2026; covers quarter ended March 31, 2026 (Exhibit 99.1).
• Updated corporate slide deck: dated May 12, 2026; will be used in investor meetings (Exhibit 99.2).
• Exhibits filed with the Form 8-K: 99.1 (press release), 99.2 (slide deck) and 104 (cover page interactive data file).

Why It Matters

• The press release contains TELA Bio’s reported quarterly earnings and financial condition for Q1 2026 (revenue, profit/loss, cash position and any commentary) — key items investors review to assess company performance.
• The updated slide deck reflects the company’s current investor messaging and may include operational highlights or metrics that affect near-term investor expectations.
• Investors should read the furnished press release and slide deck for the specific financial figures and any management commentary before making investment decisions.